Decreased appetite
2 papers
- Human trial1
- Humans1
Latest
6 in 12 monthsClinical Nutrition ESPEN
Characterizing the Adverse Event Profile of Semaglutide: A Comprehensive U.S. Food and Drug Administration Adverse Event Reporting System-Based Pharmacovigilance Study
Cross-sectional study of 43,754 peopleSemaglutide
Diabetes, Obesity & Metabolism
Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study
Randomised trial in peopleInterventions
ADA Scientific Sessions 2026 Abstract
Safety, Pharmacokinetics, and Weight Loss Effects of the Oral GLP-1/GIP Dual Agonist BGM0504 in Healthy and Overweight or Obese Adults: A Phase 1 Multiple-Ascending Dose Study
Randomised trial in 75 peopleOverweight
ADA Scientific Sessions 2026 Abstract
A Phase 1, Randomized, Double-Blind, Single-Ascending Dose Study of KAI-9531, a Novel Dual GLP-1/GIP Receptor Agonist in Development for People Living with Overweight/Obesity
Randomised trial in 49 peopleOverweight
ADA Scientific Sessions 2026 Abstract
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orforglipron: A Multiple Dose Titration Study in Chinese Participants with Obesity or Overweight with Weight-Related Comorbidities
Randomised trial in 24 peopleOrforglipron
ADA Scientific Sessions 2026 Abstract
Efficacy and Safety of Dual GLP-1/GIP Receptor Agonist HDM1005 in Obese Participants without Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
Randomised trial in 243 peopleInterventions
ADA Scientific Sessions 2025 Abstract
A Phase 3 Evaluation of CAMP-Biased GLP-1 Analog Ecnoglutide vs. Dulaglutide in Adults with Type 2 Diabetes
Randomised trial in 623 peopleType 2 diabetes
ADA Scientific Sessions 2025 Abstract
A Phase 3 Evaluation of CAMP-Biased GLP-1 Analog Ecnoglutide in Adults with Overweight or Obesity
Randomised trial in 664 peopleOverweight
ADA Scientific Sessions 2025 Abstract
Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study
Randomised trial in 64 peopleInterventions
ADA Scientific Sessions 2025 Abstract
Safety, Tolerability, and Clinical Effects of Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Agonist
Randomised trial in 54 peopleInterventions